SEC Form 4 · accession 0001209191-18-061669
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 7, 2018 · 9:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 29, 2018 | G | 1,750 | $0.00 | D | 251,533 | D | |
| Common Stock | Dec 7, 2018 | S | 10 | $24.0374 | D | 251,523 | D |
Table II — derivative securities
No Table II lines on this filing.